Date: 2017-08-24
Type of information: Construction of new premises
Compound: new capacities for drug product process development in Basel
Company: Lonza (Switzerland)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On August 24, 2017, Lonza announced that its Pharma & Biotech segment is expanding its footprint for parenteral dosage form development with a further build-out of its drug product services. This investment will significantly expand both capability and capacity of drug product services at the Stücki Science Park in Basel and will create more than 50 new positions. The expanded offering includes new capabilities for drug product process development.
Financial terms:
Latest news:
Is general: Yes
